Want to see AU:TLX full AI Analyst Report?
TLX Stock Chart & Stats
AU$16.16
-AU$0.38(-2.59%)
At close: 4:00 PM EDT
AU$16.16
-AU$0.38(-2.59%)
Day’s Range― - ―
52-Week RangeAU$8.26 - AU$18.22
Previous CloseN/A
Volume2.26M
Average Volume (3M)2.21M
Market Cap
AU$5.36B
Enterprise ValueAU$6.39B
Total Cash (Recent Filing)AU$363.61M
Total Debt (Recent Filing)AU$836.98M
Price to Earnings (P/E)105.1
Beta1.09
Next Earnings
Feb 19, 2027EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding340,330,380
10 Day Avg. Volume1,392,337
30 Day Avg. Volume2,213,820
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$25.30Price Target Upside56.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$981.16M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong double-digit revenue growth and guidance near the upper end indicate continued commercial traction across Telix’s portfolio. Sustained expansion should increase operating scale, support investment in new radiopharmaceuticals, and strengthen the company’s ability to build a broader recurring revenue base.
Improving MarginsImproving gross margins and disciplined operating expenditure suggest that growth is becoming more economically attractive rather than being purchased through disproportionate cost increases. Better profitability provides additional capacity to fund clinical development, launches, and manufacturing expansion.
Commercial PositionConsistent share gains from a two-product PSMA strategy indicate strengthening commercial execution and physician adoption in prostate cancer imaging. International expansion across roughly 24 countries broadens the addressable market and can support durable product growth beyond a single geography.
Bears Say
Rising LeverageDebt growing faster than the company’s financial flexibility increases the consequences of any earnings weakness. Elevated leverage can direct more cash toward financing obligations, constrain investment choices, and make it harder to absorb volatility while Telix continues funding its pipeline.
Weak Cash ConversionThe reversal to negative operating and free cash flow shows that reported growth has not translated consistently into internally generated cash. This creates greater dependence on balance-sheet resources or external funding, particularly while debt is elevated and research investment remains substantial.
Zircaix Regulatory SetbackThe Zircaix CRL delays certainty around a potentially important pipeline asset and places additional demands on regulatory and manufacturing execution. A prolonged resubmission process could defer commercial contribution, increase development costs, and keep capital allocated to the program for longer.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$8.26 and its highest was AU$18.22 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$5.36B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2027 which is in 120 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Aug 19, 2026. The company reported AU$0.242 earnings per share for the quarter, beating the consensus estimate of AU$0.028 by AU$0.214.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.09.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 340,330,380 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of AU$0.242 in its last earnings report, beating expectations of AU$0.028. Following the earnings report the stock price went up 3.207%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$25.30 (56.55% Upside)
AU$25.30 (56.55% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 97%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth AU$191.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.48%
12-Months-Change
Fundamentals
Return on Equity
7.11%
Trailing 12-Months
Asset Growth
14.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLX Company Deck
TLX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.View all AU:TLX earnings summariesTLX Stock 12 Month Forecast
Average Price Target
AU$25.30
▲(56.55% Upside)
Technical Analysis
Imugene
―
Immutep Ltd
―
Race Oncology Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―